nodes	percent_of_prediction	percent_of_DWPC	metapath
Octreotide—MPO—Calcipotriol—psoriasis	0.61	1	CbGbCtD
Octreotide—MPO—IL23-mediated signaling events—IL19—psoriasis	0.00734	0.0686	CbGpPWpGaD
Octreotide—MPO—IL23-mediated signaling events—IL23R—psoriasis	0.00422	0.0394	CbGpPWpGaD
Octreotide—MPO—IL23-mediated signaling events—IL23A—psoriasis	0.00359	0.0335	CbGpPWpGaD
Octreotide—SSTR4—G alpha (i) signalling events—HCAR2—psoriasis	0.00255	0.0238	CbGpPWpGaD
Octreotide—SSTR4—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.00203	0.0189	CbGpPWpGaD
Octreotide—SSTR3—G alpha (i) signalling events—HCAR2—psoriasis	0.00193	0.018	CbGpPWpGaD
Octreotide—SSTR1—G alpha (i) signalling events—HCAR2—psoriasis	0.00185	0.0173	CbGpPWpGaD
Octreotide—MPO—IL23-mediated signaling events—IL17A—psoriasis	0.00168	0.0157	CbGpPWpGaD
Octreotide—SSTR5—G alpha (i) signalling events—HCAR2—psoriasis	0.00164	0.0153	CbGpPWpGaD
Octreotide—SSTR4—Peptide ligand-binding receptors—CCL20—psoriasis	0.00157	0.0147	CbGpPWpGaD
Octreotide—MPO—IL23-mediated signaling events—IL12B—psoriasis	0.00156	0.0146	CbGpPWpGaD
Octreotide—SSTR4—GPCR ligand binding—HCAR2—psoriasis	0.00154	0.0144	CbGpPWpGaD
Octreotide—SSTR3—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.00153	0.0143	CbGpPWpGaD
Octreotide—SSTR2—G alpha (i) signalling events—HCAR2—psoriasis	0.00151	0.0142	CbGpPWpGaD
Octreotide—SSTR1—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.00147	0.0137	CbGpPWpGaD
Octreotide—SSTR1—SIDS Susceptibility Pathways—RUNX3—psoriasis	0.00133	0.0125	CbGpPWpGaD
Octreotide—SSTR4—G alpha (i) signalling events—CCL20—psoriasis	0.00132	0.0124	CbGpPWpGaD
Octreotide—SSTR5—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.0013	0.0122	CbGpPWpGaD
Octreotide—SSTR2—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.0012	0.0113	CbGpPWpGaD
Octreotide—SSTR3—Peptide ligand-binding receptors—CCL20—psoriasis	0.00119	0.0111	CbGpPWpGaD
Octreotide—SSTR3—GPCR ligand binding—HCAR2—psoriasis	0.00117	0.0109	CbGpPWpGaD
Octreotide—SSTR1—Peptide ligand-binding receptors—CCL20—psoriasis	0.00114	0.0106	CbGpPWpGaD
Octreotide—SSTR1—GPCR ligand binding—HCAR2—psoriasis	0.00112	0.0105	CbGpPWpGaD
Octreotide—SSTR2—SIDS Susceptibility Pathways—RUNX3—psoriasis	0.00109	0.0102	CbGpPWpGaD
Octreotide—SSTR1—SIDS Susceptibility Pathways—IL13—psoriasis	0.00105	0.00984	CbGpPWpGaD
Octreotide—SSTR4—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	0.00105	0.00983	CbGpPWpGaD
Octreotide—SSTR5—Peptide ligand-binding receptors—CCL20—psoriasis	0.00101	0.00944	CbGpPWpGaD
Octreotide—SSTR3—G alpha (i) signalling events—CCL20—psoriasis	0.001	0.00937	CbGpPWpGaD
Octreotide—SSTR5—GPCR ligand binding—HCAR2—psoriasis	0.000994	0.00928	CbGpPWpGaD
Octreotide—SSTR1—G alpha (i) signalling events—CCL20—psoriasis	0.000961	0.00898	CbGpPWpGaD
Octreotide—SSTR2—Peptide ligand-binding receptors—CCL20—psoriasis	0.000933	0.00871	CbGpPWpGaD
Octreotide—SSTR2—GPCR ligand binding—HCAR2—psoriasis	0.000917	0.00857	CbGpPWpGaD
Octreotide—MPO—IL23-mediated signaling events—NFKBIA—psoriasis	0.000875	0.00818	CbGpPWpGaD
Octreotide—MPO—IL23-mediated signaling events—NOS2—psoriasis	0.000875	0.00818	CbGpPWpGaD
Octreotide—SSTR4—GPCR downstream signaling—HCAR2—psoriasis	0.000871	0.00814	CbGpPWpGaD
Octreotide—SSTR2—SIDS Susceptibility Pathways—IL13—psoriasis	0.000862	0.00805	CbGpPWpGaD
Octreotide—SSTR5—G alpha (i) signalling events—CCL20—psoriasis	0.000852	0.00796	CbGpPWpGaD
Octreotide—SSTR4—GPCR ligand binding—CCL20—psoriasis	0.000801	0.00748	CbGpPWpGaD
Octreotide—SSTR3—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	0.000797	0.00745	CbGpPWpGaD
Octreotide—SSTR4—Signaling by GPCR—HCAR2—psoriasis	0.000791	0.00739	CbGpPWpGaD
Octreotide—SSTR2—G alpha (i) signalling events—CCL20—psoriasis	0.000787	0.00735	CbGpPWpGaD
Octreotide—SSTR1—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	0.000764	0.00714	CbGpPWpGaD
Octreotide—MPO—Folate Metabolism—CAT—psoriasis	0.000761	0.00711	CbGpPWpGaD
Octreotide—MPO—Vitamin B12 Metabolism—CRP—psoriasis	0.000742	0.00694	CbGpPWpGaD
Octreotide—MPO—Vitamin B12 Metabolism—APOE—psoriasis	0.000727	0.00679	CbGpPWpGaD
Octreotide—MPO—IL23-mediated signaling events—TYK2—psoriasis	0.000717	0.0067	CbGpPWpGaD
Octreotide—MPO—Folate Metabolism—IL4—psoriasis	0.000699	0.00653	CbGpPWpGaD
Octreotide—MPO—Vitamin B12 Metabolism—ICAM1—psoriasis	0.000682	0.00638	CbGpPWpGaD
Octreotide—SSTR5—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	0.000678	0.00633	CbGpPWpGaD
Octreotide—MPO—IL23-mediated signaling events—IFNG—psoriasis	0.000671	0.00627	CbGpPWpGaD
Octreotide—SSTR3—GPCR downstream signaling—HCAR2—psoriasis	0.00066	0.00617	CbGpPWpGaD
Octreotide—SSTR1—SIDS Susceptibility Pathways—IL10—psoriasis	0.000659	0.00616	CbGpPWpGaD
Octreotide—MPO—IL23-mediated signaling events—CD4—psoriasis	0.000648	0.00606	CbGpPWpGaD
Octreotide—SSTR1—GPCR downstream signaling—HCAR2—psoriasis	0.000633	0.00592	CbGpPWpGaD
Octreotide—SSTR2—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	0.000626	0.00584	CbGpPWpGaD
Octreotide—SSTR3—GPCR ligand binding—CCL20—psoriasis	0.000607	0.00567	CbGpPWpGaD
Octreotide—MPO—Selenium Micronutrient Network—CAT—psoriasis	0.000604	0.00565	CbGpPWpGaD
Octreotide—MPO—Folate Metabolism—CRP—psoriasis	0.000604	0.00564	CbGpPWpGaD
Octreotide—SSTR3—Signaling by GPCR—HCAR2—psoriasis	0.0006	0.0056	CbGpPWpGaD
Octreotide—SSTR1—GPCR ligand binding—CCL20—psoriasis	0.000582	0.00544	CbGpPWpGaD
Octreotide—SSTR1—Signaling by GPCR—HCAR2—psoriasis	0.000575	0.00537	CbGpPWpGaD
Octreotide—SSTR5—GPCR downstream signaling—HCAR2—psoriasis	0.000562	0.00525	CbGpPWpGaD
Octreotide—MPO—IL23-mediated signaling events—NFKB1—psoriasis	0.000559	0.00522	CbGpPWpGaD
Octreotide—MPO—Folate Metabolism—ICAM1—psoriasis	0.000555	0.00519	CbGpPWpGaD
Octreotide—SSTR2—SIDS Susceptibility Pathways—IL10—psoriasis	0.000539	0.00504	CbGpPWpGaD
Octreotide—MPO—Vitamin B12 Metabolism—IFNG—psoriasis	0.000519	0.00485	CbGpPWpGaD
Octreotide—SSTR2—GPCR downstream signaling—HCAR2—psoriasis	0.000518	0.00484	CbGpPWpGaD
Octreotide—SSTR5—GPCR ligand binding—CCL20—psoriasis	0.000516	0.00482	CbGpPWpGaD
Octreotide—SSTR5—Signaling by GPCR—HCAR2—psoriasis	0.00051	0.00476	CbGpPWpGaD
Octreotide—MPO—IL23-mediated signaling events—STAT3—psoriasis	0.000502	0.00469	CbGpPWpGaD
Octreotide—MPO—Selenium Micronutrient Network—CRP—psoriasis	0.00048	0.00448	CbGpPWpGaD
Octreotide—SSTR2—GPCR ligand binding—CCL20—psoriasis	0.000476	0.00445	CbGpPWpGaD
Octreotide—SSTR2—Signaling by GPCR—HCAR2—psoriasis	0.000471	0.0044	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—HCAR2—psoriasis	0.000468	0.00437	CbGpPWpGaD
Octreotide—SSTR4—GPCR downstream signaling—CCL20—psoriasis	0.000453	0.00423	CbGpPWpGaD
Octreotide—MPO—Selenium Micronutrient Network—ICAM1—psoriasis	0.000441	0.00412	CbGpPWpGaD
Octreotide—MPO—IL23-mediated signaling events—TNF—psoriasis	0.000434	0.00406	CbGpPWpGaD
Octreotide—MPO—Vitamin B12 Metabolism—NFKB1—psoriasis	0.000432	0.00404	CbGpPWpGaD
Octreotide—SSTR4—Peptide ligand-binding receptors—CXCL8—psoriasis	0.000423	0.00396	CbGpPWpGaD
Octreotide—MPO—Folate Metabolism—IFNG—psoriasis	0.000422	0.00395	CbGpPWpGaD
Octreotide—SSTR4—Signaling by GPCR—CCL20—psoriasis	0.000411	0.00384	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—TAGAP—psoriasis	0.000405	0.00379	CbGpPWpGaD
Octreotide—SSTR1—SIDS Susceptibility Pathways—CXCL8—psoriasis	0.00036	0.00337	CbGpPWpGaD
Octreotide—SSTR4—G alpha (i) signalling events—CXCL8—psoriasis	0.000357	0.00334	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—HCAR2—psoriasis	0.000354	0.00331	CbGpPWpGaD
Octreotide—MPO—Folate Metabolism—NFKB1—psoriasis	0.000352	0.00328	CbGpPWpGaD
Octreotide—MPO—IL23-mediated signaling events—IL6—psoriasis	0.000351	0.00328	CbGpPWpGaD
Octreotide—SSTR3—GPCR downstream signaling—CCL20—psoriasis	0.000343	0.00321	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—HCAR2—psoriasis	0.00034	0.00317	CbGpPWpGaD
Octreotide—MPO—C-MYB transcription factor network—CD4—psoriasis	0.000336	0.00314	CbGpPWpGaD
Octreotide—MPO—Vitamin B12 Metabolism—TNF—psoriasis	0.000336	0.00314	CbGpPWpGaD
Octreotide—MPO—Selenium Micronutrient Network—IFNG—psoriasis	0.000336	0.00314	CbGpPWpGaD
Octreotide—SSTR1—SIDS Susceptibility Pathways—JUN—psoriasis	0.000335	0.00313	CbGpPWpGaD
Octreotide—SSTR1—GPCR downstream signaling—CCL20—psoriasis	0.000329	0.00307	CbGpPWpGaD
Octreotide—SSTR1—SIDS Susceptibility Pathways—NFKB1—psoriasis	0.000322	0.00301	CbGpPWpGaD
Octreotide—SSTR3—Peptide ligand-binding receptors—CXCL8—psoriasis	0.000321	0.003	CbGpPWpGaD
Octreotide—SSTR3—Signaling by GPCR—CCL20—psoriasis	0.000312	0.00291	CbGpPWpGaD
Octreotide—SSTR1—Peptide ligand-binding receptors—CXCL8—psoriasis	0.000308	0.00287	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—TAGAP—psoriasis	0.000307	0.00287	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—HCAR2—psoriasis	0.000301	0.00281	CbGpPWpGaD
Octreotide—SSTR1—Signaling by GPCR—CCL20—psoriasis	0.000299	0.00279	CbGpPWpGaD
Octreotide—SSTR2—SIDS Susceptibility Pathways—CXCL8—psoriasis	0.000295	0.00275	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—TAGAP—psoriasis	0.000295	0.00275	CbGpPWpGaD
Octreotide—SSTR1—SIDS Susceptibility Pathways—VEGFA—psoriasis	0.000293	0.00273	CbGpPWpGaD
Octreotide—SSTR5—GPCR downstream signaling—CCL20—psoriasis	0.000292	0.00273	CbGpPWpGaD
Octreotide—SSTR4—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	0.000284	0.00265	CbGpPWpGaD
Octreotide—MPO—Selenium Micronutrient Network—NFKB1—psoriasis	0.000279	0.00261	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—HCAR2—psoriasis	0.000278	0.0026	CbGpPWpGaD
Octreotide—SSTR2—SIDS Susceptibility Pathways—JUN—psoriasis	0.000274	0.00256	CbGpPWpGaD
Octreotide—MPO—Folate Metabolism—TNF—psoriasis	0.000273	0.00255	CbGpPWpGaD
Octreotide—SSTR5—Peptide ligand-binding receptors—CXCL8—psoriasis	0.000273	0.00255	CbGpPWpGaD
Octreotide—MPO—Vitamin B12 Metabolism—IL6—psoriasis	0.000271	0.00253	CbGpPWpGaD
Octreotide—SSTR3—G alpha (i) signalling events—CXCL8—psoriasis	0.000271	0.00253	CbGpPWpGaD
Octreotide—SSTR2—GPCR downstream signaling—CCL20—psoriasis	0.000269	0.00251	CbGpPWpGaD
Octreotide—SSTR5—Signaling by GPCR—CCL20—psoriasis	0.000265	0.00247	CbGpPWpGaD
Octreotide—SSTR2—SIDS Susceptibility Pathways—NFKB1—psoriasis	0.000264	0.00247	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—TAGAP—psoriasis	0.000261	0.00244	CbGpPWpGaD
Octreotide—SSTR1—G alpha (i) signalling events—CXCL8—psoriasis	0.00026	0.00243	CbGpPWpGaD
Octreotide—SSTR2—Peptide ligand-binding receptors—CXCL8—psoriasis	0.000252	0.00235	CbGpPWpGaD
Octreotide—SSTR1—SIDS Susceptibility Pathways—TNF—psoriasis	0.000251	0.00234	CbGpPWpGaD
Octreotide—SSTR2—Signaling by GPCR—CCL20—psoriasis	0.000244	0.00228	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—CCL20—psoriasis	0.000243	0.00227	CbGpPWpGaD
Octreotide—MPO—Folate Metabolism—TP53—psoriasis	0.000241	0.00225	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—TAGAP—psoriasis	0.000241	0.00225	CbGpPWpGaD
Octreotide—SSTR2—SIDS Susceptibility Pathways—VEGFA—psoriasis	0.000239	0.00224	CbGpPWpGaD
Octreotide—SSTR5—G alpha (i) signalling events—CXCL8—psoriasis	0.00023	0.00215	CbGpPWpGaD
Octreotide—MPO—Folate Metabolism—IL6—psoriasis	0.000221	0.00206	CbGpPWpGaD
Octreotide—MPO—Selenium Micronutrient Network—TNF—psoriasis	0.000217	0.00203	CbGpPWpGaD
Octreotide—SSTR4—GPCR ligand binding—CXCL8—psoriasis	0.000216	0.00202	CbGpPWpGaD
Octreotide—SSTR3—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	0.000215	0.00201	CbGpPWpGaD
Octreotide—SSTR2—G alpha (i) signalling events—CXCL8—psoriasis	0.000212	0.00198	CbGpPWpGaD
Octreotide—SSTR1—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	0.000206	0.00193	CbGpPWpGaD
Octreotide—SSTR2—SIDS Susceptibility Pathways—TNF—psoriasis	0.000205	0.00192	CbGpPWpGaD
Octreotide—SSTR1—SIDS Susceptibility Pathways—IL6—psoriasis	0.000202	0.00189	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—CCL20—psoriasis	0.000184	0.00172	CbGpPWpGaD
Octreotide—SSTR5—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	0.000183	0.00171	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—CCL20—psoriasis	0.000176	0.00165	CbGpPWpGaD
Octreotide—MPO—Selenium Micronutrient Network—IL6—psoriasis	0.000175	0.00164	CbGpPWpGaD
Octreotide—SSTR2—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	0.000169	0.00158	CbGpPWpGaD
Octreotide—SSTR2—SIDS Susceptibility Pathways—IL6—psoriasis	0.000166	0.00155	CbGpPWpGaD
Octreotide—SSTR3—GPCR ligand binding—CXCL8—psoriasis	0.000164	0.00153	CbGpPWpGaD
Octreotide—SSTR1—GPCR ligand binding—CXCL8—psoriasis	0.000157	0.00147	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—CCL20—psoriasis	0.000156	0.00146	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—CCL20—psoriasis	0.000144	0.00135	CbGpPWpGaD
Octreotide—SSTR5—GPCR ligand binding—CXCL8—psoriasis	0.000139	0.0013	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—SOCS1—psoriasis	0.000134	0.00125	CbGpPWpGaD
Octreotide—SSTR2—GPCR ligand binding—CXCL8—psoriasis	0.000129	0.0012	CbGpPWpGaD
Octreotide—SSTR4—Signaling by GPCR—TYK2—psoriasis	0.000127	0.00119	CbGpPWpGaD
Octreotide—SSTR4—GPCR downstream signaling—CXCL8—psoriasis	0.000122	0.00114	CbGpPWpGaD
Octreotide—SSTR4—Signaling by GPCR—CXCL8—psoriasis	0.000111	0.00104	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—SOCS1—psoriasis	0.000101	0.000947	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—APOE—psoriasis	9.87e-05	0.000922	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—LEP—psoriasis	9.87e-05	0.000922	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—SOCS1—psoriasis	9.72e-05	0.000908	CbGpPWpGaD
Octreotide—SSTR3—Signaling by GPCR—TYK2—psoriasis	9.66e-05	0.000903	CbGpPWpGaD
Octreotide—SSTR3—GPCR downstream signaling—CXCL8—psoriasis	9.26e-05	0.000865	CbGpPWpGaD
Octreotide—SSTR1—Signaling by GPCR—TYK2—psoriasis	9.26e-05	0.000865	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—NFKBIA—psoriasis	9.2e-05	0.000859	CbGpPWpGaD
Octreotide—SSTR1—GPCR downstream signaling—CXCL8—psoriasis	8.88e-05	0.00083	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—SOCS1—psoriasis	8.62e-05	0.000805	CbGpPWpGaD
Octreotide—SSTR3—Signaling by GPCR—CXCL8—psoriasis	8.41e-05	0.000786	CbGpPWpGaD
Octreotide—SSTR5—Signaling by GPCR—TYK2—psoriasis	8.22e-05	0.000768	CbGpPWpGaD
Octreotide—SSTR1—Signaling by GPCR—CXCL8—psoriasis	8.07e-05	0.000754	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—SOCS1—psoriasis	7.95e-05	0.000743	CbGpPWpGaD
Octreotide—SSTR5—GPCR downstream signaling—CXCL8—psoriasis	7.88e-05	0.000736	CbGpPWpGaD
Octreotide—SSTR2—Signaling by GPCR—TYK2—psoriasis	7.58e-05	0.000708	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—TYK2—psoriasis	7.53e-05	0.000704	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—LEP—psoriasis	7.48e-05	0.000699	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—APOE—psoriasis	7.48e-05	0.000699	CbGpPWpGaD
Octreotide—Paraesthesia—Hydrocortisone—psoriasis	7.29e-05	0.000257	CcSEcCtD
Octreotide—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	7.28e-05	0.000257	CcSEcCtD
Octreotide—SSTR2—GPCR downstream signaling—CXCL8—psoriasis	7.27e-05	0.000679	CbGpPWpGaD
Octreotide—Urticaria—Cyclosporine—psoriasis	7.25e-05	0.000256	CcSEcCtD
Octreotide—Myalgia—Dexamethasone—psoriasis	7.23e-05	0.000255	CcSEcCtD
Octreotide—Myalgia—Betamethasone—psoriasis	7.23e-05	0.000255	CcSEcCtD
Octreotide—Body temperature increased—Cyclosporine—psoriasis	7.22e-05	0.000255	CcSEcCtD
Octreotide—Abdominal pain—Cyclosporine—psoriasis	7.22e-05	0.000255	CcSEcCtD
Octreotide—Anxiety—Dexamethasone—psoriasis	7.21e-05	0.000255	CcSEcCtD
Octreotide—Anxiety—Betamethasone—psoriasis	7.21e-05	0.000255	CcSEcCtD
Octreotide—Vomiting—Mycophenolic acid—psoriasis	7.18e-05	0.000253	CcSEcCtD
Octreotide—SSTR1—Signaling Pathways—APOE—psoriasis	7.17e-05	0.00067	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—LEP—psoriasis	7.17e-05	0.00067	CbGpPWpGaD
Octreotide—SSTR5—Signaling by GPCR—CXCL8—psoriasis	7.15e-05	0.000668	CbGpPWpGaD
Octreotide—Discomfort—Betamethasone—psoriasis	7.15e-05	0.000252	CcSEcCtD
Octreotide—Discomfort—Dexamethasone—psoriasis	7.15e-05	0.000252	CcSEcCtD
Octreotide—Dyspepsia—Hydrocortisone—psoriasis	7.14e-05	0.000252	CcSEcCtD
Octreotide—Rash—Mycophenolic acid—psoriasis	7.12e-05	0.000251	CcSEcCtD
Octreotide—Dermatitis—Mycophenolic acid—psoriasis	7.11e-05	0.000251	CcSEcCtD
Octreotide—Pain—Prednisolone—psoriasis	7.11e-05	0.000251	CcSEcCtD
Octreotide—Hepatitis—Methotrexate—psoriasis	7.1e-05	0.000251	CcSEcCtD
Octreotide—Urticaria—Mycophenolate mofetil—psoriasis	7.08e-05	0.00025	CcSEcCtD
Octreotide—Headache—Mycophenolic acid—psoriasis	7.07e-05	0.00025	CcSEcCtD
Octreotide—Decreased appetite—Hydrocortisone—psoriasis	7.05e-05	0.000249	CcSEcCtD
Octreotide—Pharyngitis—Methotrexate—psoriasis	7.05e-05	0.000249	CcSEcCtD
Octreotide—Abdominal pain—Mycophenolate mofetil—psoriasis	7.04e-05	0.000249	CcSEcCtD
Octreotide—Body temperature increased—Mycophenolate mofetil—psoriasis	7.04e-05	0.000249	CcSEcCtD
Octreotide—Gastrointestinal disorder—Hydrocortisone—psoriasis	7.01e-05	0.000247	CcSEcCtD
Octreotide—Fatigue—Hydrocortisone—psoriasis	7e-05	0.000247	CcSEcCtD
Octreotide—Vision blurred—Prednisone—psoriasis	6.97e-05	0.000246	CcSEcCtD
Octreotide—SSTR3—Signaling Pathways—NFKBIA—psoriasis	6.97e-05	0.000651	CbGpPWpGaD
Octreotide—Musculoskeletal discomfort—Triamcinolone—psoriasis	6.96e-05	0.000246	CcSEcCtD
Octreotide—Pain—Hydrocortisone—psoriasis	6.94e-05	0.000245	CcSEcCtD
Octreotide—Oedema—Betamethasone—psoriasis	6.93e-05	0.000245	CcSEcCtD
Octreotide—Oedema—Dexamethasone—psoriasis	6.93e-05	0.000245	CcSEcCtD
Octreotide—Anaphylactic shock—Betamethasone—psoriasis	6.93e-05	0.000245	CcSEcCtD
Octreotide—Anaphylactic shock—Dexamethasone—psoriasis	6.93e-05	0.000245	CcSEcCtD
Octreotide—Insomnia—Triamcinolone—psoriasis	6.91e-05	0.000244	CcSEcCtD
Octreotide—Infection—Dexamethasone—psoriasis	6.89e-05	0.000243	CcSEcCtD
Octreotide—Infection—Betamethasone—psoriasis	6.89e-05	0.000243	CcSEcCtD
Octreotide—Ill-defined disorder—Prednisone—psoriasis	6.86e-05	0.000242	CcSEcCtD
Octreotide—Paraesthesia—Triamcinolone—psoriasis	6.86e-05	0.000242	CcSEcCtD
Octreotide—Feeling abnormal—Prednisolone—psoriasis	6.85e-05	0.000242	CcSEcCtD
Octreotide—Visual impairment—Methotrexate—psoriasis	6.85e-05	0.000242	CcSEcCtD
Octreotide—Anaemia—Prednisone—psoriasis	6.84e-05	0.000242	CcSEcCtD
Octreotide—Shock—Dexamethasone—psoriasis	6.82e-05	0.000241	CcSEcCtD
Octreotide—Shock—Betamethasone—psoriasis	6.82e-05	0.000241	CcSEcCtD
Octreotide—Dyspnoea—Triamcinolone—psoriasis	6.81e-05	0.000241	CcSEcCtD
Octreotide—Nervous system disorder—Dexamethasone—psoriasis	6.8e-05	0.00024	CcSEcCtD
Octreotide—Nervous system disorder—Betamethasone—psoriasis	6.8e-05	0.00024	CcSEcCtD
Octreotide—Agitation—Prednisone—psoriasis	6.8e-05	0.00024	CcSEcCtD
Octreotide—Thrombocytopenia—Betamethasone—psoriasis	6.79e-05	0.00024	CcSEcCtD
Octreotide—Thrombocytopenia—Dexamethasone—psoriasis	6.79e-05	0.00024	CcSEcCtD
Octreotide—Tachycardia—Dexamethasone—psoriasis	6.77e-05	0.000239	CcSEcCtD
Octreotide—Tachycardia—Betamethasone—psoriasis	6.77e-05	0.000239	CcSEcCtD
Octreotide—Hypersensitivity—Cyclosporine—psoriasis	6.73e-05	0.000238	CcSEcCtD
Octreotide—Dyspepsia—Triamcinolone—psoriasis	6.73e-05	0.000238	CcSEcCtD
Octreotide—Nausea—Mycophenolic acid—psoriasis	6.7e-05	0.000237	CcSEcCtD
Octreotide—Hyperhidrosis—Dexamethasone—psoriasis	6.7e-05	0.000237	CcSEcCtD
Octreotide—Hyperhidrosis—Betamethasone—psoriasis	6.7e-05	0.000237	CcSEcCtD
Octreotide—Feeling abnormal—Hydrocortisone—psoriasis	6.69e-05	0.000236	CcSEcCtD
Octreotide—SSTR1—Signaling Pathways—NFKBIA—psoriasis	6.68e-05	0.000624	CbGpPWpGaD
Octreotide—Malaise—Prednisone—psoriasis	6.67e-05	0.000236	CcSEcCtD
Octreotide—Vertigo—Prednisone—psoriasis	6.65e-05	0.000235	CcSEcCtD
Octreotide—Gastrointestinal pain—Hydrocortisone—psoriasis	6.64e-05	0.000234	CcSEcCtD
Octreotide—Syncope—Prednisone—psoriasis	6.64e-05	0.000234	CcSEcCtD
Octreotide—Tinnitus—Methotrexate—psoriasis	6.62e-05	0.000234	CcSEcCtD
Octreotide—Anorexia—Dexamethasone—psoriasis	6.61e-05	0.000233	CcSEcCtD
Octreotide—Anorexia—Betamethasone—psoriasis	6.61e-05	0.000233	CcSEcCtD
Octreotide—Urticaria—Prednisolone—psoriasis	6.6e-05	0.000233	CcSEcCtD
Octreotide—SSTR2—Signaling by GPCR—CXCL8—psoriasis	6.6e-05	0.000617	CbGpPWpGaD
Octreotide—Cardiac disorder—Methotrexate—psoriasis	6.59e-05	0.000233	CcSEcCtD
Octreotide—Fatigue—Triamcinolone—psoriasis	6.59e-05	0.000233	CcSEcCtD
Octreotide—Hypersensitivity—Mycophenolate mofetil—psoriasis	6.56e-05	0.000232	CcSEcCtD
Octreotide—SSTR4—Signaling Pathways—CXCL8—psoriasis	6.56e-05	0.000613	CbGpPWpGaD
Octreotide—Asthenia—Cyclosporine—psoriasis	6.55e-05	0.000231	CcSEcCtD
Octreotide—Pain—Triamcinolone—psoriasis	6.53e-05	0.000231	CcSEcCtD
Octreotide—Loss of consciousness—Prednisone—psoriasis	6.5e-05	0.00023	CcSEcCtD
Octreotide—Pruritus—Cyclosporine—psoriasis	6.46e-05	0.000228	CcSEcCtD
Octreotide—Urticaria—Hydrocortisone—psoriasis	6.45e-05	0.000228	CcSEcCtD
Octreotide—Immune system disorder—Methotrexate—psoriasis	6.42e-05	0.000227	CcSEcCtD
Octreotide—Body temperature increased—Hydrocortisone—psoriasis	6.42e-05	0.000227	CcSEcCtD
Octreotide—Abdominal pain—Hydrocortisone—psoriasis	6.42e-05	0.000227	CcSEcCtD
Octreotide—Convulsion—Prednisone—psoriasis	6.41e-05	0.000226	CcSEcCtD
Octreotide—Asthenia—Mycophenolate mofetil—psoriasis	6.39e-05	0.000226	CcSEcCtD
Octreotide—Hypertension—Prednisone—psoriasis	6.39e-05	0.000226	CcSEcCtD
Octreotide—SSTR5—Signaling Pathways—APOE—psoriasis	6.36e-05	0.000594	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—LEP—psoriasis	6.36e-05	0.000594	CbGpPWpGaD
Octreotide—Musculoskeletal discomfort—Betamethasone—psoriasis	6.32e-05	0.000223	CcSEcCtD
Octreotide—Musculoskeletal discomfort—Dexamethasone—psoriasis	6.32e-05	0.000223	CcSEcCtD
Octreotide—Pruritus—Mycophenolate mofetil—psoriasis	6.3e-05	0.000223	CcSEcCtD
Octreotide—Arthralgia—Prednisone—psoriasis	6.3e-05	0.000222	CcSEcCtD
Octreotide—Myalgia—Prednisone—psoriasis	6.3e-05	0.000222	CcSEcCtD
Octreotide—Feeling abnormal—Triamcinolone—psoriasis	6.3e-05	0.000222	CcSEcCtD
Octreotide—Anxiety—Prednisone—psoriasis	6.28e-05	0.000222	CcSEcCtD
Octreotide—Alopecia—Methotrexate—psoriasis	6.28e-05	0.000222	CcSEcCtD
Octreotide—Insomnia—Dexamethasone—psoriasis	6.27e-05	0.000222	CcSEcCtD
Octreotide—Insomnia—Betamethasone—psoriasis	6.27e-05	0.000222	CcSEcCtD
Octreotide—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	6.26e-05	0.000221	CcSEcCtD
Octreotide—Diarrhoea—Cyclosporine—psoriasis	6.25e-05	0.000221	CcSEcCtD
Octreotide—SSTR4—Signaling by GPCR—IL6—psoriasis	6.24e-05	0.000583	CbGpPWpGaD
Octreotide—Paraesthesia—Dexamethasone—psoriasis	6.23e-05	0.00022	CcSEcCtD
Octreotide—Paraesthesia—Betamethasone—psoriasis	6.23e-05	0.00022	CcSEcCtD
Octreotide—Discomfort—Prednisone—psoriasis	6.22e-05	0.00022	CcSEcCtD
Octreotide—Mental disorder—Methotrexate—psoriasis	6.22e-05	0.00022	CcSEcCtD
Octreotide—Erythema—Methotrexate—psoriasis	6.18e-05	0.000218	CcSEcCtD
Octreotide—Malnutrition—Methotrexate—psoriasis	6.18e-05	0.000218	CcSEcCtD
Octreotide—Hypersensitivity—Prednisolone—psoriasis	6.12e-05	0.000216	CcSEcCtD
Octreotide—Dyspepsia—Betamethasone—psoriasis	6.1e-05	0.000216	CcSEcCtD
Octreotide—Dyspepsia—Dexamethasone—psoriasis	6.1e-05	0.000216	CcSEcCtD
Octreotide—SSTR4—Signaling Pathways—JUN—psoriasis	6.1e-05	0.00057	CbGpPWpGaD
Octreotide—Diarrhoea—Mycophenolate mofetil—psoriasis	6.1e-05	0.000215	CcSEcCtD
Octreotide—Urticaria—Triamcinolone—psoriasis	6.07e-05	0.000214	CcSEcCtD
Octreotide—Body temperature increased—Triamcinolone—psoriasis	6.04e-05	0.000213	CcSEcCtD
Octreotide—Dizziness—Cyclosporine—psoriasis	6.04e-05	0.000213	CcSEcCtD
Octreotide—Anaphylactic shock—Prednisone—psoriasis	6.04e-05	0.000213	CcSEcCtD
Octreotide—Oedema—Prednisone—psoriasis	6.04e-05	0.000213	CcSEcCtD
Octreotide—Decreased appetite—Betamethasone—psoriasis	6.03e-05	0.000213	CcSEcCtD
Octreotide—Decreased appetite—Dexamethasone—psoriasis	6.03e-05	0.000213	CcSEcCtD
Octreotide—Infection—Prednisone—psoriasis	6e-05	0.000212	CcSEcCtD
Octreotide—Gastrointestinal disorder—Betamethasone—psoriasis	5.99e-05	0.000211	CcSEcCtD
Octreotide—Gastrointestinal disorder—Dexamethasone—psoriasis	5.99e-05	0.000211	CcSEcCtD
Octreotide—Back pain—Methotrexate—psoriasis	5.98e-05	0.000211	CcSEcCtD
Octreotide—Hypersensitivity—Hydrocortisone—psoriasis	5.98e-05	0.000211	CcSEcCtD
Octreotide—Fatigue—Dexamethasone—psoriasis	5.98e-05	0.000211	CcSEcCtD
Octreotide—Fatigue—Betamethasone—psoriasis	5.98e-05	0.000211	CcSEcCtD
Octreotide—Shock—Prednisone—psoriasis	5.94e-05	0.00021	CcSEcCtD
Octreotide—Pain—Betamethasone—psoriasis	5.93e-05	0.000209	CcSEcCtD
Octreotide—Pain—Dexamethasone—psoriasis	5.93e-05	0.000209	CcSEcCtD
Octreotide—SSTR5—Signaling Pathways—NFKBIA—psoriasis	5.93e-05	0.000554	CbGpPWpGaD
Octreotide—Nervous system disorder—Prednisone—psoriasis	5.92e-05	0.000209	CcSEcCtD
Octreotide—Tachycardia—Prednisone—psoriasis	5.89e-05	0.000208	CcSEcCtD
Octreotide—Dizziness—Mycophenolate mofetil—psoriasis	5.89e-05	0.000208	CcSEcCtD
Octreotide—SSTR4—Signaling Pathways—NFKB1—psoriasis	5.87e-05	0.000548	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—APOE—psoriasis	5.87e-05	0.000548	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—LEP—psoriasis	5.87e-05	0.000548	CbGpPWpGaD
Octreotide—Skin disorder—Prednisone—psoriasis	5.87e-05	0.000207	CcSEcCtD
Octreotide—Hyperhidrosis—Prednisone—psoriasis	5.84e-05	0.000206	CcSEcCtD
Octreotide—Vision blurred—Methotrexate—psoriasis	5.83e-05	0.000206	CcSEcCtD
Octreotide—Asthenia—Hydrocortisone—psoriasis	5.82e-05	0.000206	CcSEcCtD
Octreotide—Vomiting—Cyclosporine—psoriasis	5.81e-05	0.000205	CcSEcCtD
Octreotide—Rash—Cyclosporine—psoriasis	5.76e-05	0.000203	CcSEcCtD
Octreotide—Anorexia—Prednisone—psoriasis	5.76e-05	0.000203	CcSEcCtD
Octreotide—Dermatitis—Cyclosporine—psoriasis	5.75e-05	0.000203	CcSEcCtD
Octreotide—Pruritus—Hydrocortisone—psoriasis	5.74e-05	0.000203	CcSEcCtD
Octreotide—Ill-defined disorder—Methotrexate—psoriasis	5.74e-05	0.000203	CcSEcCtD
Octreotide—Headache—Cyclosporine—psoriasis	5.72e-05	0.000202	CcSEcCtD
Octreotide—Anaemia—Methotrexate—psoriasis	5.72e-05	0.000202	CcSEcCtD
Octreotide—Feeling abnormal—Dexamethasone—psoriasis	5.71e-05	0.000202	CcSEcCtD
Octreotide—Feeling abnormal—Betamethasone—psoriasis	5.71e-05	0.000202	CcSEcCtD
Octreotide—SSTR3—Signaling Pathways—TYK2—psoriasis	5.71e-05	0.000533	CbGpPWpGaD
Octreotide—Gastrointestinal pain—Dexamethasone—psoriasis	5.67e-05	0.0002	CcSEcCtD
Octreotide—Gastrointestinal pain—Betamethasone—psoriasis	5.67e-05	0.0002	CcSEcCtD
Octreotide—Vomiting—Mycophenolate mofetil—psoriasis	5.66e-05	0.0002	CcSEcCtD
Octreotide—Hypersensitivity—Triamcinolone—psoriasis	5.63e-05	0.000199	CcSEcCtD
Octreotide—Rash—Mycophenolate mofetil—psoriasis	5.62e-05	0.000198	CcSEcCtD
Octreotide—Dermatitis—Mycophenolate mofetil—psoriasis	5.61e-05	0.000198	CcSEcCtD
Octreotide—Headache—Mycophenolate mofetil—psoriasis	5.58e-05	0.000197	CcSEcCtD
Octreotide—Malaise—Methotrexate—psoriasis	5.58e-05	0.000197	CcSEcCtD
Octreotide—Vertigo—Methotrexate—psoriasis	5.56e-05	0.000196	CcSEcCtD
Octreotide—Diarrhoea—Hydrocortisone—psoriasis	5.55e-05	0.000196	CcSEcCtD
Octreotide—Urticaria—Betamethasone—psoriasis	5.51e-05	0.000195	CcSEcCtD
Octreotide—Urticaria—Dexamethasone—psoriasis	5.51e-05	0.000195	CcSEcCtD
Octreotide—Musculoskeletal discomfort—Prednisone—psoriasis	5.5e-05	0.000194	CcSEcCtD
Octreotide—Dizziness—Prednisolone—psoriasis	5.5e-05	0.000194	CcSEcCtD
Octreotide—Asthenia—Triamcinolone—psoriasis	5.48e-05	0.000194	CcSEcCtD
Octreotide—Body temperature increased—Betamethasone—psoriasis	5.48e-05	0.000194	CcSEcCtD
Octreotide—Abdominal pain—Betamethasone—psoriasis	5.48e-05	0.000194	CcSEcCtD
Octreotide—Abdominal pain—Dexamethasone—psoriasis	5.48e-05	0.000194	CcSEcCtD
Octreotide—Body temperature increased—Dexamethasone—psoriasis	5.48e-05	0.000194	CcSEcCtD
Octreotide—SSTR1—Signaling Pathways—TYK2—psoriasis	5.47e-05	0.000511	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—NFKBIA—psoriasis	5.47e-05	0.000511	CbGpPWpGaD
Octreotide—Insomnia—Prednisone—psoriasis	5.46e-05	0.000193	CcSEcCtD
Octreotide—Nausea—Cyclosporine—psoriasis	5.42e-05	0.000192	CcSEcCtD
Octreotide—Paraesthesia—Prednisone—psoriasis	5.42e-05	0.000192	CcSEcCtD
Octreotide—Pruritus—Triamcinolone—psoriasis	5.41e-05	0.000191	CcSEcCtD
Octreotide—Cough—Methotrexate—psoriasis	5.4e-05	0.000191	CcSEcCtD
Octreotide—Dizziness—Hydrocortisone—psoriasis	5.37e-05	0.00019	CcSEcCtD
Octreotide—Convulsion—Methotrexate—psoriasis	5.36e-05	0.000189	CcSEcCtD
Octreotide—SSTR4—Signaling Pathways—VEGFA—psoriasis	5.33e-05	0.000498	CbGpPWpGaD
Octreotide—Dyspepsia—Prednisone—psoriasis	5.32e-05	0.000188	CcSEcCtD
Octreotide—Nausea—Mycophenolate mofetil—psoriasis	5.29e-05	0.000187	CcSEcCtD
Octreotide—SSTR4—Signaling Pathways—STAT3—psoriasis	5.27e-05	0.000493	CbGpPWpGaD
Octreotide—Chest pain—Methotrexate—psoriasis	5.26e-05	0.000186	CcSEcCtD
Octreotide—Arthralgia—Methotrexate—psoriasis	5.26e-05	0.000186	CcSEcCtD
Octreotide—Myalgia—Methotrexate—psoriasis	5.26e-05	0.000186	CcSEcCtD
Octreotide—Decreased appetite—Prednisone—psoriasis	5.25e-05	0.000185	CcSEcCtD
Octreotide—Rash—Prednisolone—psoriasis	5.24e-05	0.000185	CcSEcCtD
Octreotide—Dermatitis—Prednisolone—psoriasis	5.23e-05	0.000185	CcSEcCtD
Octreotide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	5.23e-05	0.000185	CcSEcCtD
Octreotide—Fatigue—Prednisone—psoriasis	5.21e-05	0.000184	CcSEcCtD
Octreotide—Headache—Prednisolone—psoriasis	5.21e-05	0.000184	CcSEcCtD
Octreotide—Discomfort—Methotrexate—psoriasis	5.2e-05	0.000184	CcSEcCtD
Octreotide—Constipation—Prednisone—psoriasis	5.16e-05	0.000182	CcSEcCtD
Octreotide—Vomiting—Hydrocortisone—psoriasis	5.16e-05	0.000182	CcSEcCtD
Octreotide—Rash—Hydrocortisone—psoriasis	5.12e-05	0.000181	CcSEcCtD
Octreotide—Dermatitis—Hydrocortisone—psoriasis	5.11e-05	0.000181	CcSEcCtD
Octreotide—Headache—Hydrocortisone—psoriasis	5.08e-05	0.00018	CcSEcCtD
Octreotide—Dizziness—Triamcinolone—psoriasis	5.05e-05	0.000178	CcSEcCtD
Octreotide—Anaphylactic shock—Methotrexate—psoriasis	5.05e-05	0.000178	CcSEcCtD
Octreotide—Infection—Methotrexate—psoriasis	5.01e-05	0.000177	CcSEcCtD
Octreotide—Feeling abnormal—Prednisone—psoriasis	4.98e-05	0.000176	CcSEcCtD
Octreotide—Asthenia—Dexamethasone—psoriasis	4.97e-05	0.000176	CcSEcCtD
Octreotide—Asthenia—Betamethasone—psoriasis	4.97e-05	0.000176	CcSEcCtD
Octreotide—SSTR3—Signaling Pathways—CXCL8—psoriasis	4.97e-05	0.000464	CbGpPWpGaD
Octreotide—Nervous system disorder—Methotrexate—psoriasis	4.95e-05	0.000175	CcSEcCtD
Octreotide—Thrombocytopenia—Methotrexate—psoriasis	4.94e-05	0.000175	CcSEcCtD
Octreotide—Gastrointestinal pain—Prednisone—psoriasis	4.94e-05	0.000174	CcSEcCtD
Octreotide—Nausea—Prednisolone—psoriasis	4.94e-05	0.000174	CcSEcCtD
Octreotide—Pruritus—Dexamethasone—psoriasis	4.91e-05	0.000173	CcSEcCtD
Octreotide—Pruritus—Betamethasone—psoriasis	4.91e-05	0.000173	CcSEcCtD
Octreotide—Skin disorder—Methotrexate—psoriasis	4.9e-05	0.000173	CcSEcCtD
Octreotide—Hyperhidrosis—Methotrexate—psoriasis	4.88e-05	0.000172	CcSEcCtD
Octreotide—Vomiting—Triamcinolone—psoriasis	4.86e-05	0.000172	CcSEcCtD
Octreotide—SSTR5—Signaling Pathways—TYK2—psoriasis	4.85e-05	0.000453	CbGpPWpGaD
Octreotide—Nausea—Hydrocortisone—psoriasis	4.82e-05	0.00017	CcSEcCtD
Octreotide—Rash—Triamcinolone—psoriasis	4.82e-05	0.00017	CcSEcCtD
Octreotide—Dermatitis—Triamcinolone—psoriasis	4.81e-05	0.00017	CcSEcCtD
Octreotide—Anorexia—Methotrexate—psoriasis	4.81e-05	0.00017	CcSEcCtD
Octreotide—Urticaria—Prednisone—psoriasis	4.8e-05	0.000169	CcSEcCtD
Octreotide—Headache—Triamcinolone—psoriasis	4.79e-05	0.000169	CcSEcCtD
Octreotide—Abdominal pain—Prednisone—psoriasis	4.77e-05	0.000169	CcSEcCtD
Octreotide—Body temperature increased—Prednisone—psoriasis	4.77e-05	0.000169	CcSEcCtD
Octreotide—SSTR1—Signaling Pathways—CXCL8—psoriasis	4.76e-05	0.000445	CbGpPWpGaD
Octreotide—Diarrhoea—Betamethasone—psoriasis	4.74e-05	0.000168	CcSEcCtD
Octreotide—Diarrhoea—Dexamethasone—psoriasis	4.74e-05	0.000168	CcSEcCtD
Octreotide—SSTR3—Signaling by GPCR—IL6—psoriasis	4.73e-05	0.000441	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—JUN—psoriasis	4.62e-05	0.000432	CbGpPWpGaD
Octreotide—Musculoskeletal discomfort—Methotrexate—psoriasis	4.6e-05	0.000162	CcSEcCtD
Octreotide—Dizziness—Dexamethasone—psoriasis	4.59e-05	0.000162	CcSEcCtD
Octreotide—Dizziness—Betamethasone—psoriasis	4.59e-05	0.000162	CcSEcCtD
Octreotide—Insomnia—Methotrexate—psoriasis	4.56e-05	0.000161	CcSEcCtD
Octreotide—Nausea—Triamcinolone—psoriasis	4.54e-05	0.00016	CcSEcCtD
Octreotide—Paraesthesia—Methotrexate—psoriasis	4.53e-05	0.00016	CcSEcCtD
Octreotide—SSTR1—Signaling by GPCR—IL6—psoriasis	4.53e-05	0.000423	CbGpPWpGaD
Octreotide—Dyspnoea—Methotrexate—psoriasis	4.5e-05	0.000159	CcSEcCtD
Octreotide—Somnolence—Methotrexate—psoriasis	4.49e-05	0.000158	CcSEcCtD
Octreotide—SSTR2—Signaling Pathways—TYK2—psoriasis	4.48e-05	0.000418	CbGpPWpGaD
Octreotide—Hypersensitivity—Prednisone—psoriasis	4.45e-05	0.000157	CcSEcCtD
Octreotide—SSTR3—Signaling Pathways—NFKB1—psoriasis	4.45e-05	0.000415	CbGpPWpGaD
Octreotide—Dyspepsia—Methotrexate—psoriasis	4.44e-05	0.000157	CcSEcCtD
Octreotide—SSTR1—Signaling Pathways—JUN—psoriasis	4.43e-05	0.000414	CbGpPWpGaD
Octreotide—Vomiting—Betamethasone—psoriasis	4.41e-05	0.000156	CcSEcCtD
Octreotide—Vomiting—Dexamethasone—psoriasis	4.41e-05	0.000156	CcSEcCtD
Octreotide—Decreased appetite—Methotrexate—psoriasis	4.39e-05	0.000155	CcSEcCtD
Octreotide—Rash—Dexamethasone—psoriasis	4.37e-05	0.000154	CcSEcCtD
Octreotide—Rash—Betamethasone—psoriasis	4.37e-05	0.000154	CcSEcCtD
Octreotide—Dermatitis—Betamethasone—psoriasis	4.37e-05	0.000154	CcSEcCtD
Octreotide—Dermatitis—Dexamethasone—psoriasis	4.37e-05	0.000154	CcSEcCtD
Octreotide—Gastrointestinal disorder—Methotrexate—psoriasis	4.36e-05	0.000154	CcSEcCtD
Octreotide—Fatigue—Methotrexate—psoriasis	4.35e-05	0.000154	CcSEcCtD
Octreotide—Headache—Betamethasone—psoriasis	4.34e-05	0.000153	CcSEcCtD
Octreotide—Headache—Dexamethasone—psoriasis	4.34e-05	0.000153	CcSEcCtD
Octreotide—Asthenia—Prednisone—psoriasis	4.33e-05	0.000153	CcSEcCtD
Octreotide—Pain—Methotrexate—psoriasis	4.32e-05	0.000152	CcSEcCtD
Octreotide—Pruritus—Prednisone—psoriasis	4.27e-05	0.000151	CcSEcCtD
Octreotide—SSTR1—Signaling Pathways—NFKB1—psoriasis	4.26e-05	0.000398	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—CXCL8—psoriasis	4.23e-05	0.000395	CbGpPWpGaD
Octreotide—Feeling abnormal—Methotrexate—psoriasis	4.16e-05	0.000147	CcSEcCtD
Octreotide—Diarrhoea—Prednisone—psoriasis	4.13e-05	0.000146	CcSEcCtD
Octreotide—Gastrointestinal pain—Methotrexate—psoriasis	4.13e-05	0.000146	CcSEcCtD
Octreotide—Nausea—Betamethasone—psoriasis	4.12e-05	0.000145	CcSEcCtD
Octreotide—Nausea—Dexamethasone—psoriasis	4.12e-05	0.000145	CcSEcCtD
Octreotide—SSTR3—Signaling Pathways—VEGFA—psoriasis	4.04e-05	0.000377	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—TP53—psoriasis	4.02e-05	0.000376	CbGpPWpGaD
Octreotide—SSTR5—Signaling by GPCR—IL6—psoriasis	4.02e-05	0.000375	CbGpPWpGaD
Octreotide—Urticaria—Methotrexate—psoriasis	4.01e-05	0.000142	CcSEcCtD
Octreotide—SSTR3—Signaling Pathways—STAT3—psoriasis	4e-05	0.000373	CbGpPWpGaD
Octreotide—Dizziness—Prednisone—psoriasis	3.99e-05	0.000141	CcSEcCtD
Octreotide—Body temperature increased—Methotrexate—psoriasis	3.99e-05	0.000141	CcSEcCtD
Octreotide—Abdominal pain—Methotrexate—psoriasis	3.99e-05	0.000141	CcSEcCtD
Octreotide—SSTR5—Signaling Pathways—JUN—psoriasis	3.93e-05	0.000367	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—CXCL8—psoriasis	3.9e-05	0.000364	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—VEGFA—psoriasis	3.87e-05	0.000362	CbGpPWpGaD
Octreotide—Vomiting—Prednisone—psoriasis	3.84e-05	0.000136	CcSEcCtD
Octreotide—SSTR1—Signaling Pathways—STAT3—psoriasis	3.83e-05	0.000358	CbGpPWpGaD
Octreotide—Rash—Prednisone—psoriasis	3.81e-05	0.000134	CcSEcCtD
Octreotide—Dermatitis—Prednisone—psoriasis	3.8e-05	0.000134	CcSEcCtD
Octreotide—Headache—Prednisone—psoriasis	3.78e-05	0.000134	CcSEcCtD
Octreotide—SSTR5—Signaling Pathways—NFKB1—psoriasis	3.78e-05	0.000353	CbGpPWpGaD
Octreotide—Hypersensitivity—Methotrexate—psoriasis	3.72e-05	0.000131	CcSEcCtD
Octreotide—SSTR2—Signaling by GPCR—IL6—psoriasis	3.71e-05	0.000346	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—IL6—psoriasis	3.68e-05	0.000344	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—JUN—psoriasis	3.63e-05	0.000339	CbGpPWpGaD
Octreotide—Asthenia—Methotrexate—psoriasis	3.62e-05	0.000128	CcSEcCtD
Octreotide—Nausea—Prednisone—psoriasis	3.59e-05	0.000127	CcSEcCtD
Octreotide—Pruritus—Methotrexate—psoriasis	3.57e-05	0.000126	CcSEcCtD
Octreotide—SSTR2—Signaling Pathways—NFKB1—psoriasis	3.49e-05	0.000326	CbGpPWpGaD
Octreotide—Diarrhoea—Methotrexate—psoriasis	3.45e-05	0.000122	CcSEcCtD
Octreotide—SSTR5—Signaling Pathways—VEGFA—psoriasis	3.43e-05	0.000321	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—STAT3—psoriasis	3.4e-05	0.000317	CbGpPWpGaD
Octreotide—Dizziness—Methotrexate—psoriasis	3.34e-05	0.000118	CcSEcCtD
Octreotide—Vomiting—Methotrexate—psoriasis	3.21e-05	0.000113	CcSEcCtD
Octreotide—Rash—Methotrexate—psoriasis	3.18e-05	0.000112	CcSEcCtD
Octreotide—Dermatitis—Methotrexate—psoriasis	3.18e-05	0.000112	CcSEcCtD
Octreotide—SSTR2—Signaling Pathways—VEGFA—psoriasis	3.17e-05	0.000296	CbGpPWpGaD
Octreotide—Headache—Methotrexate—psoriasis	3.16e-05	0.000112	CcSEcCtD
Octreotide—SSTR2—Signaling Pathways—STAT3—psoriasis	3.14e-05	0.000293	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—TP53—psoriasis	3.05e-05	0.000285	CbGpPWpGaD
Octreotide—Nausea—Methotrexate—psoriasis	3e-05	0.000106	CcSEcCtD
Octreotide—SSTR1—Signaling Pathways—TP53—psoriasis	2.92e-05	0.000273	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—IL6—psoriasis	2.79e-05	0.000261	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—IL6—psoriasis	2.68e-05	0.00025	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—TP53—psoriasis	2.59e-05	0.000242	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—TP53—psoriasis	2.39e-05	0.000224	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—IL6—psoriasis	2.37e-05	0.000222	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—IL6—psoriasis	2.19e-05	0.000205	CbGpPWpGaD
